Cycle Pharmaceuticals Extends Tender Offer for Applied Therapeutics…

Event summary

Cycle Pharmaceuticals extended its tender offer for Applied Therapeutics until February 2, 2026.
Approximately 75.9 million shares (49.21% of outstanding shares) have been validly tendered as of January 29, 2026.
The offer includes $0.088 per share plus one non-tradeable contingent value right per share.
The deal is conditioned on the tender of a majority of Applied Therapeutics' outstanding shares.

The big picture

Cycle Pharmaceuticals' extension of its tender offer for Applied Therapeutics reflects a strategic push to consolidate its position in the rare disease pharmaceutical market. The deal, if completed, would bolster Cycle's portfolio in metabolic, immunology, urology, and oncology conditions. The extension indicates potential challenges in securing the necessary majority stake, highlighting the competitive dynamics within the biotech acquisition space.

What we're watching

Deal Completion: Whether Cycle Pharmaceuticals can secure a majority of Applied Therapeutics' shares by the new deadline.
Strategic Integration: How Cycle Pharmaceuticals plans to integrate Applied Therapeutics' rare disease focus into its existing portfolio.
Market Reaction: The impact of the extended tender offer on Applied Therapeutics' stock price and investor sentiment.